LCINDX Semi-Annual Rebalance/Reconstitution Notice
Lenexa, KS -- June 17, 2015 -- Loncar Investments, LLC today announced the result of the semi-annual rebalance and reconstitution of the Loncar Cancer Immunotherapy Index (LCINDX). Given the growing number of public companies working in cancer immunotherapy, the Committee that governs the index increased the target number of index components to 30 from 25. LCINDX will now combine 23 small-to mid-cap biotechnology companies (up from 19) with 7 large cap pharmaceutical companies (up from 6).
As part of today’s reconstitution and additions, Adaptimmune Therapeutics (Nasdaq: ADAP), Aduro BioTech (Nasdaq: ADRO), Immune Design (Nasdaq: IMDZ), Oncothyreon (Nasdaq: ONTY), and Pfizer (NYSE: PFE) have been added to the LCINDX index. In addition, all index holdings have been rebalanced to equal weight today.
The index is rebalanced and reconstituted semi-annually, and the next date this is scheduled to take place is on the third Tuesday of December (December 15, 2015).
Why immunotherapy: Cancer immunotherapy has become an important sector in the biotechnology space and is changing the way many cancers are treated. While traditional medicines like chemotherapies often give cancer a broad punch, the benefit of using immunotherapy is derived from the immune system's dynamic nature and the way it can more precisely be tailored to fight a patient's disease. Some immunotherapies have already exhibited uncommon results in clinical trials including partial and complete responses in late stage cancer patients.
Professional sector index: LCINDX is a professional equal-weighted index of 30 top immunotherapy companies rebalanced and reconstituted on a semi-annual basis. Price and return data are independently calculated on a daily basis by Indxx, LLC. Quotes for the symbol "LCINDX" can be found on the Bloomberg Professional service, www.LoncarIndex.com, and other financial data providers. LCINDX is a sector index similar to Technology sector indices (Internet, Cyber Security, Cloud Computing, etc.). Sector indices allow investors to track interest areas more precisely than broad indices. Additional info can be found at the index’s dedicated website, www.LoncarIndex.com.
Index provider: Loncar Investments, LLC, the provider of the LCINDX index, is committed to making the biotechnology space more approachable to a wider range of investors. The company is principally owned by biotech investor Brad Loncar. Mr. Loncar manages a biotech-focused family portfolio from his Lenexa, Kansas office. He is an independent investor and has no direct business relationship with any biotechnology companies, important factors in the company’s ability to manage an unbiased index. Mr. Loncar can be followed on Twitter at @bradloncar and his commentary is available at www.loncarblog.com.